CSTL

Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Get 50% Off Elite

Peers: VCYT MYGN NEO MDXH BDSX XGN GH NTRA LUCD TEM

| Held by: VTI IWM VXF IWN IBB DFAS FESM VTWO SCHA DFAC

Scroll to Statements

Index	RUT
Market Cap	1.06B
Enterprise Value	822.13M
Income	-23.01M
Sales	377.13M
Book/sh	15.55
Cash/sh	9.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	883
IPO	Jul 25, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	2.82
P/B	2.22
P/C	3.83
P/FCF	268.49
EV/EBITDA	-
EV/Sales	2.18
Quick Ratio	5.12
Current Ratio	5.28
Debt/Eq	0.08
LT Debt/Eq	0.06
Option/Short	Yes / Yes

EPS (ttm)	-0.77
EPS next Y	-0.62
EPS next Q	-0.15
EPS this Y	-2.95%
EPS next Y	26.96%
EPS next 5Y	80.00%
EPS past 3/5Y	31.36% -8.93%
Sales past 3/5Y	35.94% 40.60%
EPS Y/Y TTM	-81.20%
Sales Y/Y TTM	9.78%
EPS Q/Q	-677.91%
Sales Q/Q	23.90%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	62.62% 9.90%

Insider Own	2.00%
Insider Trans	-36.67%
Inst Own	87.26%
Inst Trans	-5.75%
ROA	-4.03%
ROE	-4.87%
ROIC	-4.52%
Gross Margin	74.10%
Oper. Margin	-7.43%
Profit Margin	-6.10%
SMA20	0.30%
SMA50	0.51%
SMA200	22.28%
Trades

Shs Outstand	30.77M
Shs Float	30.20M
Short Float	6.98%
Short Ratio	5.54
Short Interest	2.11M
52W High	44.28 -22.09%
52W Low	17.72 94.67%
Volatility	6.80% 5.58%
ATR (14)	1.89
RSI (14)	50.47
Beta	0.96
Rel Volume	0.00
Avg Volume	380.59K
Volume	0

Perf Week	0.88%
Perf Month	4.20%
Perf Quarter	16.48%
Perf Half Y	82.73%
Perf YTD	-11.31%
Perf Year	-0.92%
Perf 3Y	100.81%
Perf 5Y	-33.24%
Perf 10Y	-
Recom	1.10
Target Price	48.20
Prev Close	34.50
Price	34.50
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$48.20

Implied Upside

+39.7%

Analysts11incl. previous ratings

Rating Distribution11 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 29, 2026	Initiated	MMizuho	Outperform	$60	+73.9%
Jun 25, 2026	Initiated	RRoth Capital	Buy	$40	+15.9%
Dec 14, 2023	Initiated	GGuggenheim	Buy	$25	-27.5%
Jan 05, 2023	Initiated	BScotiabank	Sector Outperform	$54	+56.5%
Jan 07, 2022	Initiated	SStephens	Overweight	$59	+71.0%
Apr 30, 2021	Initiated	LLake Street	Buy	$94	+172.5%
Nov 10, 2020	Initiated	KKeyBanc Capital Markets	Overweight	$70	+102.9%
Dec 27, 2019	Reiterated	CCanaccord Genuity	Buy	$34 → $35	+1.4%
Aug 19, 2019	Initiated	SSVB Leerink	Outperform	$28	-18.8%
Aug 19, 2019	Initiated	RRobert W. Baird	Outperform	$27	-21.7%
Aug 19, 2019	Initiated	CCanaccord Genuity	Buy	$26	-24.6%
Aug 19, 2019	Initiated	BBTIG Research	Buy	$25	-27.5%

Nov-12-26 07:00AM	Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture (PR Newswire)
Nov-11-26 04:30PM	Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference (PR Newswire)
07:00AM	DecisionDx-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging (PR Newswire)
Nov-05-26 08:49PM	Castle Biosciences Beats And Raises For A Third Time As TissueCypher Carries A Softening Dermatology Franchise (Earnings Whispers)
04:05PM	Castle Biosciences Reports Third Quarter 2026 Results (PR Newswire)
07:28PM	Loading…
Oct-28-26 07:28PM	Castle Biosciences Faces A Higher Bar After Two Raises As TissueCypher Matures (Earnings Whispers) +6.29%
07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Oct-15-26 07:00AM	Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026 (PR Newswire)
Oct-12-26 04:30PM	ACG 2026 Data Show TissueCypher Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus (PR Newswire)
Sep-30-26 04:30PM	Late-Breaking EADV 2026 Data Support Use of DecisionDx-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management (PR Newswire)
Sep-28-26 07:00AM	New Study Shows That TissueCypher Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus (PR Newswire)
Sep-24-26 04:30PM	New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx (PR Newswire)
Sep-22-26 07:00AM	Castle Biosciences to Open New Laboratory Facility in Scottsdale (PR Newswire)
Sep-15-26 07:00AM	New Decision Modeling Study Demonstrates TissueCypher Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus (PR Newswire) +6.16%
Sep-09-26 04:30PM	JAAD Publication Shows Improved Performance of DecisionDx-SCC (PR Newswire)
07:00AM	Loading…
Aug-20-26 07:00AM	Castle Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-17-26 07:00AM	Castle Biosciences Approved for Dual Listing on Nasdaq Texas (PR Newswire)
Aug-03-26 10:55AM	Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison (IPO-Edge.com) +8.54%
Jul-31-26 01:03AM	Castle Biosciences Inc (CSTL) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% to $103. ... (GuruFocus.com)
Jul-30-26 04:05PM	Castle Biosciences Reports Second Quarter 2026 Results (PR Newswire) +9.53%
Jul-22-26 07:00AM	Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference (PR Newswire)
Jul-14-26 04:30PM	Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test (PR Newswire)
Jul-09-26 07:00AM	Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 (PR Newswire)
Jul-01-26 05:41PM	SkylineDxs Merlin CP-GEP Granted FDA Breakthrough Device Designation (Exec Edge)
Jun-25-26 04:30PM	DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy (PR Newswire) +6.07%
Jun-23-26 07:00AM	Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal (PR Newswire)
Jun-19-26 07:00AM	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-16-26 07:00AM	Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus (PR Newswire)
May-13-26 07:00AM	Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference (PR Newswire)
May-12-26 07:00AM	Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation (PR Newswire)
04:05PM	Loading…
May-06-26 04:05PM	Castle Biosciences Reports First Quarter 2026 Results (PR Newswire) -22.26%
May-05-26 07:00AM	Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month (PR Newswire)
May-04-26 07:00AM	New Data at DDW 2026 Show TissueCypher Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus (PR Newswire)
Apr-21-26 07:00AM	Castle Biosciences to Present New Data Demonstrating DecisionDx-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS (PR Newswire)
Apr-15-26 07:00AM	Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 (PR Newswire)
Apr-10-26 07:00AM	Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year (PR Newswire)
Mar-27-26 09:05AM	Castle Biosciences' DecisionDx-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 (PR Newswire)
Mar-13-26 11:02AM	Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB (GlobeNewswire)
Mar-09-26 07:00AM	DecisionDx-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk (GlobeNewswire)
Mar-04-26 04:30PM	Castle Biosciences to Present Data at SSO 2026 on DecisionDx-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB (GlobeNewswire)
Mar-03-26 04:30PM	Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas (GlobeNewswire)
Mar-02-26 11:43AM	LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata (Zacks) -5.34%
09:10AM	REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria (Zacks)
Feb-27-26 12:46PM	RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus (Zacks) -7.25%
12:35PM	PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View (Zacks)
12:08PM	TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line (Zacks)
12:06PM	PRGO Q4 Earnings Miss, Sales Beat, Stock Down on Weak 2026 View (Zacks)
11:14AM	Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline (Zacks)
09:49AM	Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
09:34AM	Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway (Zacks)
12:06AM	Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... (GuruFocus.com)
Feb-26-26 06:00PM	Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
05:48PM	Castle Biosciences Q4 Earnings Call Highlights (MarketBeat)
04:05PM	Castle Biosciences Reports Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
11:44AM	Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up (Zacks)
11:40AM	Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change (Zacks)
10:54AM	ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance (Zacks)
10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks)
10:40AM	IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks (Zacks)
10:08AM	Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:52AM	ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
09:21AM	Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss (Zacks)
09:02AM	UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance (Zacks)
Feb-25-26 11:03AM	BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:01AM	IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress (Zacks)
10:56AM	JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations (Zacks)
10:21AM	RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up (Zacks)
09:12AM	Corcept's Q4 Earnings and Revenues Fall Short of Estimates (Zacks)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
08:55AM	Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y (Zacks)
Feb-24-26 12:08PM	AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
Feb-23-26 11:12AM	Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks)
10:47AM	FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug (Zacks)
09:06AM	Viatris Stock to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-20-26 10:20AM	Insmed Lags on Q4 Earnings, Stock Gains on 2026 Brinsupri Sales View (Zacks) -6.80%
09:59AM	Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down (Zacks)
Feb-19-26 05:46PM	Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire) -6.92%
11:59AM	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth (Zacks)
10:00AM	Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
09:53AM	Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? (Zacks)
09:45AM	Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
07:34AM	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up (Zacks)
Feb-18-26 11:31AM	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
11:24AM	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:41AM	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients (Zacks)
Feb-17-26 10:05AM	Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? (Zacks)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
09:15AM	Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Feb-13-26 12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
Feb-12-26 10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
Feb-11-26 10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
Feb-10-26 10:45AM	Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards? (Zacks)
10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
10:22AM	Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
09:35AM	Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Juvenal Tobin W	Chief Commercial Officer	Nov 09 '26	Sale	32.67	3,288	107,419	35,565	Nov 12 04:13 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 11 '26	Sale	35.04	2,828	99,104	32,737	Nov 12 04:13 PM
TOBIN JUVENAL	Officer	Nov 11 '26	Proposed Sale	35.07	3,195	112,033		Nov 12 08:30 AM
Tobin Juvenal	Chief Commercial Officer	Nov 09 '26	Proposed Sale	34.38	13,154	452,235		Nov 09 06:37 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 02 '26	Sale	36.10	8,580	309,752	3,904	Nov 04 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Nov 02 '26	Sale	36.10	5,916	213,578	1,396	Nov 04 04:07 PM
Derek Maetzold	Officer	Nov 02 '26	Proposed Sale	34.94	21,438	749,044		Nov 02 05:28 PM
Juvenal Tobin W	Chief Commercial Officer	Oct 28 '26	Sale	36.42	6,578	239,591	38,853	Oct 30 04:06 PM
Juvenal Tobin W	Chief Commercial Officer	Oct 26 '26	Sale	33.08	3,288	108,767	45,431	Oct 28 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 19 '26	Sale	31.91	8,580	273,788	12,484	Oct 21 04:18 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 19 '26	Sale	31.91	5,916	188,780	4,114	Oct 21 04:18 PM
Juvenal Tobin W	Chief Commercial Officer	Oct 12 '26	Sale	33.64	3,288	110,608	48,719	Oct 14 04:06 PM
Tobin Juvenal	Chief Commercial Officer	Oct 12 '26	Proposed Sale	32.76	13,154	430,925		Oct 13 08:52 AM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 05 '26	Option Exercise	2.39	8,165	19,514	29,644	Oct 07 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 05 '26	Sale	35.57	8,580	305,156	21,064	Oct 07 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Oct 05 '26	Sale	35.57	5,916	210,408	6,832	Oct 07 04:10 PM
Derek Maetzold	Officer	Oct 05 '26	Proposed Sale	36.65	28,992	1,062,557		Oct 05 06:24 PM
Oelschlager Kristen M	Chief Operating Officer	Oct 01 '26	Option Exercise	3.38	4,153	14,037	17,509	Oct 05 04:07 PM
Oelschlager Kristen M	Chief Operating Officer	Oct 01 '26	Sale	35.95	4,153	149,318	13,356	Oct 05 04:07 PM
KRISTEN OELSCHLAGER	Officer	Oct 01 '26	Proposed Sale	35.53	4,153	147,556		Oct 01 04:24 PM
Juvenal Tobin W	Chief Commercial Officer	Sep 29 '26	Sale	35.50	5,543	196,765	53,041	Oct 01 04:21 PM
Juvenal Tobin W	Chief Commercial Officer	Sep 30 '26	Sale	34.20	1,034	35,363	52,007	Oct 01 04:21 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 21 '26	Option Exercise	2.39	8,580	20,506	30,059	Sep 23 04:27 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 21 '26	Sale	35.33	8,580	303,166	21,479	Sep 23 04:27 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 21 '26	Sale	35.33	5,916	209,036	9,550	Sep 23 04:27 PM
Juvenal Tobin W	Chief Commercial Officer	Sep 15 '26	Sale	35.14	3,294	115,758	58,584	Sep 16 04:20 PM
Juvenal Tobin W	Chief Commercial Officer	Sep 14 '26	Sale	32.32	3,306	106,863	61,878	Sep 16 04:20 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 11 '26	Option Exercise	2.39	8,584	20,516	30,063	Sep 15 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 11 '26	Sale	32.02	8,584	274,862	21,479	Sep 15 04:08 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Sep 11 '26	Sale	32.02	5,934	190,008	12,268	Sep 15 04:08 PM
Tobin Juvenal	Chief Commercial Officer	Sep 14 '26	Proposed Sale	33.44	13,177	440,639		Sep 14 06:00 PM
Derek Maetzold	Officer	Sep 11 '26	Proposed Sale	32.33	29,014	938,023		Sep 11 06:53 PM
Oelschlager Kristen M	Chief Operating Officer	Sep 01 '26	Option Exercise	3.38	4,152	14,034	17,508	Sep 03 04:07 PM
Oelschlager Kristen M	Chief Operating Officer	Sep 01 '26	Sale	33.39	4,152	138,643	13,356	Sep 03 04:07 PM
Juvenal Tobin W	Chief Commercial Officer	Aug 31 '26	Sale	32.81	1,730	56,761	65,184	Sep 02 04:07 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 28 '26	Option Exercise	2.39	12,428	29,703	33,907	Sep 01 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 28 '26	Sale	33.20	12,428	412,571	21,479	Sep 01 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 28 '26	Sale	33.20	6,132	203,562	11,256	Sep 01 04:12 PM
Juvenal Tobin W	Chief Commercial Officer	Aug 25 '26	Sale	35.04	9,050	317,112	66,914	Aug 27 04:38 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 25 '26	Sale	34.42	12,384	426,277	72,649	Aug 26 04:16 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 24 '26	Sale	33.69	12,218	411,588	85,033	Aug 26 04:16 PM
Tobin Juvenal	Chief Commercial Officer	Aug 25 '26	Proposed Sale	35.00	22,500	787,500		Aug 25 05:46 PM
Kristen M. Oelschlager	Officer	Aug 24 '26	Proposed Sale	34.20	24,602	841,388		Aug 24 04:47 PM
Juvenal Tobin W	Chief Commercial Officer	Aug 17 '26	Sale	29.59	1,730	51,191	75,964	Aug 19 04:11 PM
Stokes Frank	Chief Financial Officer	Aug 14 '26	Sale	29.77	24,908	741,511	35,177	Aug 18 04:10 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 14 '26	Option Exercise	2.39	1,100	2,629	22,579	Aug 18 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 14 '26	Sale	30.02	6,132	184,083	11,534	Aug 18 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 14 '26	Sale	30.02	1,100	33,022	21,479	Aug 18 04:09 PM
FRANKLIN M. STOKES	Officer	Aug 14 '26	Proposed Sale	29.77	24,908	741,494		Aug 14 06:50 PM
Derek Maetzold	Officer	Aug 14 '26	Proposed Sale	29.62	25,792	763,959		Aug 14 05:38 PM
Juvenal Tobin W	Chief Commercial Officer	Nov 24 '25	Sale	38.39	1,301	49,945	77,694	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 04 '26	Option Exercise	2.39	20,356	48,651	41,835	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 05 '26	Option Exercise	2.39	2,546	6,085	24,025	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 04 '26	Sale	31.11	20,356	633,261	21,479	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 04 '26	Sale	31.11	15,085	469,284	20,080	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 05 '26	Sale	30.68	2,546	78,114	21,479	Aug 06 04:14 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 05 '26	Sale	30.68	1,029	31,571	19,607	Aug 06 04:14 PM
Oelschlager Kristen M	Chief Operating Officer	Aug 03 '26	Sale	29.77	8,586	255,622	13,288	Aug 05 04:18 PM
Juvenal Tobin W	Chief Commercial Officer	Jul 31 '26	Sale	29.31	17,310	507,302	80,725	Aug 04 04:36 PM
Juvenal Tobin W	Chief Commercial Officer	Aug 03 '26	Sale	28.25	1,730	48,872	78,995	Aug 04 04:36 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 03 '26	Option Exercise	2.39	10,664	25,487	32,143	Aug 04 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 31 '26	Option Exercise	2.39	6,480	15,487	27,959	Aug 04 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 03 '26	Sale	30.35	10,664	323,684	21,479	Aug 04 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Aug 03 '26	Sale	30.35	7,829	237,634	27,009	Aug 04 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 31 '26	Sale	30.15	6,480	195,385	21,479	Aug 04 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 31 '26	Sale	30.15	3,673	110,748	30,606	Aug 04 04:35 PM
Tobin Juvenal	Chief Commercial Officer	Jul 31 '26	Proposed Sale	28.00	22,500	630,000		Jul 31 04:52 PM
Derek Maetzold	Officer	Jul 31 '26	Proposed Sale	28.00	67,662	1,894,536		Jul 31 04:52 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 27 '26	Option Exercise	2.39	6,214	14,851	27,693	Jul 29 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 27 '26	Sale	24.16	6,214	150,160	21,479	Jul 29 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 27 '26	Sale	24.16	3,622	87,523	11,812	Jul 29 04:09 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 14 '26	Option Exercise	2.39	550	1,314	22,029	Jul 16 04:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 14 '26	Sale	22.92	3,622	83,016	12,090	Jul 16 04:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 14 '26	Sale	22.92	550	12,606	21,479	Jul 16 04:16 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 01 '26	Option Exercise	2.39	6,214	14,851	27,693	Jul 06 04:25 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 01 '26	Sale	24.29	6,214	150,938	21,479	Jul 06 04:25 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jul 01 '26	Sale	24.29	3,622	87,978	12,368	Jul 06 04:25 PM
Oelschlager Kristen M	Chief Operating Officer	Jul 01 '26	Sale	24.42	8,586	209,650	21,874	Jul 06 04:24 PM
Derek Maetzold	Officer	Jul 01 '26	Proposed Sale	24.71	23,844	589,185		Jul 01 05:35 PM
Oelschlager Kristen M	Chief Operating Officer	Jun 16 '26	Sale	20.71	8,587	177,837	30,460	Jun 18 04:19 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 15 '26	Option Exercise	2.39	550	1,314	22,029	Jun 17 05:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 15 '26	Sale	20.66	3,622	74,831	12,646	Jun 17 05:39 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 15 '26	Sale	20.66	550	11,363	21,479	Jun 17 05:39 PM
KRISTEN OELSCHLAGER	Officer	Jun 16 '26	Proposed Sale	20.66	29,911	617,961		Jun 16 04:35 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 01 '26	Option Exercise	2.39	6,214	14,851	27,693	Jun 03 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 01 '26	Sale	20.86	6,214	129,605	21,479	Jun 03 04:15 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Jun 01 '26	Sale	20.86	3,622	75,544	1,668	Jun 03 04:15 PM
Derek Maetzold	Officer	Jun 01 '26	Proposed Sale	20.97	14,008	293,748		Jun 01 05:39 PM
Juvenal Tobin W	Chief Commercial Officer	May 21 '26	Option Exercise	3.38	11,210	37,890	98,035	May 26 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 21 '26	Option Exercise	2.39	420	1,004	21,899	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 20 '26	Option Exercise	2.39	130	311	21,609	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 21 '26	Sale	20.20	2,763	55,802	1,946	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 20 '26	Sale	20.00	859	17,182	2,158	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 21 '26	Sale	20.20	420	8,482	21,479	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 20 '26	Sale	20.00	130	2,600	21,479	May 22 04:12 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 07 '26	Option Exercise	2.39	6,214	14,851	27,693	May 11 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 07 '26	Sale	22.15	6,214	137,663	21,479	May 11 04:06 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	May 07 '26	Sale	22.15	3,622	80,241	2,224	May 11 04:06 PM
Derek Maetzold	Officer	May 07 '26	Proposed Sale	19.24	14,008	269,514		May 07 04:56 PM
MAETZOLD DEREK J	Pres. & Chief Exec. Officer	Apr 21 '26	Option Exercise	2.39	550	1,314	22,029	Apr 23 04:16 PM

Castle Biosciences, Inc. is a molecular diagnostics company, which offers innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett's esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

FounderMr. Derek J. Maetzold

CFO & TreasurerMr. Frank Stokes

Chief Operating OfficerMs. Kristen M. Oelschlager R.N.

Chief Commercial OfficerMr. Tobin W. Juvenal

Vice President of Investor Relations & Corporate AffairsMs. Camilla Zuckero

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

Castle Biosciences Inc

Upgrade your Finviz experience

All the Features.
Half the Price.